SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
SCHEDULE 13G
(RULE 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO 13d-2(b)
(AMENDMENT NO. __)1
ATHEROGENICS, INC.
------------------
(Name of Issuer)
COMMON STOCK
------------
(Title of Class of Securities)
047439 10 4
-----------
(CUSIP Number)
MARCH 14, 2001
--------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
|_| Rule 13d-1(b)
|X| Rule 13d-1(c)
|_| Rule 13d-1(d)
--------------------
1 The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 or otherwise subject to the liabilities of that section of the Act but
shall be subject to all other provisions of the Act (however, SEE the NOTES).
--------------------------- ---------------------------
CUSIP NO. 047439 10 4 13G PAGE 2 OF 9 PAGES
--------------------------- ---------------------------
--------- ----------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BIOTECHNOLOGY VALUE FUND, L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
--------- ----------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
--------- ----------------------------------------------------------------------
3 SEC USE ONLY
--------- ----------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------- ----------------------------------------------------------------------
NUMBER 5 SOLE VOTING POWER
OF 0
SHARES ----- -----------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 763,000
EACH ----- -----------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON 0
WITH ----- -----------------------------------------------
8 SHARED DISPOSITIVE POWER
763,000
--------- ----------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
763,000
--------- ----------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
--------- ----------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
3.2%
--------- ----------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
--------- ----------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
--------------------------- ---------------------------
CUSIP NO. 047439 10 4 13G PAGE 3 OF 9 PAGES
--------------------------- ---------------------------
--------- ----------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BIOTECHNOLOGY VALUE FUND II, L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
--------- ----------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
--------- ----------------------------------------------------------------------
3 SEC USE ONLY
--------- ----------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------- ----------------------------------------------------------------------
NUMBER 5 SOLE VOTING POWER
OF 0
SHARES ----- -----------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 452,600
EACH ----- -----------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON 0
WITH ----- -----------------------------------------------
8 SHARED DISPOSITIVE POWER
452,600
--------- ----------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
452,600
--------- ----------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
--------- ----------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
1.9%
--------- ----------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
--------- ----------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
--------------------------- ---------------------------
CUSIP NO. 047439 10 4 13G PAGE 4 OF 9 PAGES
--------------------------- ---------------------------
--------- ----------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BVF INVESTMENTS, L.L.C.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
--------- ----------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
--------- ----------------------------------------------------------------------
3 SEC USE ONLY
--------- ----------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------- ----------------------------------------------------------------------
NUMBER 5 SOLE VOTING POWER
OF 0
SHARES ----- -----------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 1,047,300
EACH ----- -----------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON 0
WITH ----- -----------------------------------------------
8 SHARED DISPOSITIVE POWER
1,047,300
--------- ----------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,047,300
--------- ----------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
--------- ----------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
4.4%
--------- ----------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
OO
--------- ----------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
--------------------------- ---------------------------
CUSIP NO. 047439 10 4 13G PAGE 5 OF 9 PAGES
--------------------------- ---------------------------
--------- ----------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BVF PARTNERS L.P.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
--------- ----------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
--------- ----------------------------------------------------------------------
3 SEC USE ONLY
--------- ----------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------- ----------------------------------------------------------------------
NUMBER 5 SOLE VOTING POWER
OF 0
SHARES ----- -----------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 2,372,900
EACH ----- -----------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON 0
WITH ----- -----------------------------------------------
8 SHARED DISPOSITIVE POWER
2,372,900
--------- ----------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,372,900
--------- ----------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
--------- ----------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.9%
--------- ----------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
PN
--------- ----------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
--------------------------- ---------------------------
CUSIP NO. 047439 10 4 13G PAGE 6 OF 9 PAGES
--------------------------- ---------------------------
--------- ----------------------------------------------------------------------
1 NAME OF REPORTING PERSON:
BVF INC.
I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY):
--------- ----------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) |X| (b) |_|
--------- ----------------------------------------------------------------------
3 SEC USE ONLY
--------- ----------------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE
--------- ----------------------------------------------------------------------
NUMBER 5 SOLE VOTING POWER
OF 0
SHARES ----- -----------------------------------------------
BENEFICIALLY 6 SHARED VOTING POWER
OWNED BY 2,372,900
EACH ----- -----------------------------------------------
REPORTING 7 SOLE DISPOSITIVE POWER
PERSON 0
WITH ----- -----------------------------------------------
8 SHARED DISPOSITIVE POWER
2,372,900
--------- ----------------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,372,900
--------- ----------------------------------------------------------------------
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES* |_|
--------- ----------------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
9.9%
--------- ----------------------------------------------------------------------
12 TYPE OF REPORTING PERSON*
IA, CO
--------- ----------------------------------------------------------------------
* SEE INSTRUCTIONS BEFORE FILLING OUT!
--------------------------- ---------------------------
CUSIP NO. 047439 10 4 13G PAGE 7 OF 9 PAGES
--------------------------- ---------------------------
ITEM 1(a). NAME OF ISSUER:
Atherogenics, Inc. ("Atherogenics")
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
8995 Westside Parkway
Alpharetta, Georgia 30004
ITEM 2(a). NAME OF PERSON FILING:
This Schedule 13G is being filed on behalf of the following
persons* (the "Reporting Persons"):
(i) Biotechnology Value Fund, L.P. ("BVF")
(ii) Biotechnology Value Fund II, L.P. ("BVF2")
(iii) BVF Investments, L.L.C. ("Investments")
(iv) BVF Partners L.P. ("Partners")
(v) BVF Inc. ("BVF Inc.")
* Attached as Exhibit 1 is a copy of an agreement among
the Reporting Persons filing (as specified
hereinabove) that this Schedule 13G is being filed on
behalf of each of them.
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE:
The principal business office of the Reporting Persons
comprising the group filing this Schedule 13G is located at 227 West Monroe
Street, Suite 4800, Chicago, Illinois, 60606.
ITEM 2(c). CITIZENSHIP:
BVF: a Delaware limited partnership
BVF2: a Delaware limited partnership
Investments: a Delaware limited liability company
Partners: a Delaware limited partnership
BVF Inc.: a Delaware corporation
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock.
ITEM 2(e). CUSIP NUMBER:
047439 10 4
--------------------------- ---------------------------
CUSIP NO. 047439 10 4 13G PAGE 8 OF 9 PAGES
--------------------------- ---------------------------
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), OR
13d-2(b) OR (c) CHECK WHETHER THE PERSON FILING IS: ONE OF
THE FOLLOWING
Not applicable as this Schedule 13G is filed pursuant to Rule
13d 1(c).
ITEM 4. OWNERSHIP:
The information in items 1 and 5 through 11 on the cover pages
(pp. 2 - 6) on this Schedule 13G is hereby incorporated by reference.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
If this statement is being filed to report the fact that as of
the date hereof the Reporting Persons have ceased to be the beneficial owner of
more than five percent of the class of securities check the following. |_|
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER
PERSON:
BVF shares voting and dispositive power over the shares of the
common stock it beneficially owns with Partners. BVF2 also shares voting and
dispositive power over the shares of the common stock it beneficially owns with
Partners. Investments also shares voting and dispositive power over the shares
of the common stock it beneficially owns with Partners. Partners and BVF Inc.
share voting and dispositive power over the shares of the common stock they
beneficially own with, in addition to BVF, BVF2 and Investments, certain managed
accounts on whose behalf Partners, as investment manager, purchased such shares.
None of the managed accounts individually owns more than 5% of the common stock
of Atherogenics.
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY:
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF A GROUP:
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
Not applicable.
--------------------------- ---------------------------
CUSIP NO. 047439 10 4 13G PAGE 9 OF 9 PAGES
--------------------------- ---------------------------
ITEM 10. CERTIFICATION
By signing below I certify that, to the best of my knowledge
and belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control of
the issuer of the securities and were not acquired and are not held in
connection with or as a participant in any transaction having that purpose or
effect.
After reasonable inquiry and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.
Dated: March 21, 2001
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-------------------
Mark N. Lampert
President
BIOTECHNOLOGY VALUE FUND II, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-------------------
Mark N. Lampert
President
BVF INVESTMENTS, L.L.C.
By: BVF Partners L.P., its manager
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-------------------
Mark N. Lampert
President
BVF INC.
By: /s/ MARK N. LAMPERT
-------------------
Mark N. Lampert
President
EXHIBIT 1
AGREEMENT REGARDING JOINT FILING
The undersigned, Biotechnology Value Fund, L.P., a Delaware limited
partnership, Biotechnology Value Fund II, L.P., a Delaware limited partnership,
BVF Investments, L.L.C., a Delaware limited liability company, BVF Partners
L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation,
hereby agree and acknowledge that the information required by Schedule 13G, to
which this Agreement is attached as an exhibit, is filed on behalf of each of
them. The undersigned further agree that any amendments or supplements thereto
shall also be filed on behalf of each of them.
Dated: March 21, 2001
BIOTECHNOLOGY VALUE FUND, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-------------------
Mark N. Lampert
President
BIOTECHNOLOGY VALUE FUND II, L.P.
By: BVF Partners L.P., its general partner
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-------------------
Mark N. Lampert
President
BVF INVESTMENTS, L.L.C.
By: BVF Partners L.P., its manager
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-------------------
Mark N. Lampert
President
BVF PARTNERS L.P.
By: BVF Inc., its general partner
By: /s/ MARK N. LAMPERT
-------------------
Mark N. Lampert
President
BVF INC.
By: /s/ MARK N. LAMPERT
-------------------
Mark N. Lampert
President